Skip to content

Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): a randomized controlled trial.

Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): a randomized controlled trial. - ACCESS study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON42056
Enrollment
86
Registered
2015-04-08
Start date
2015-04-01
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

After a short self-management educational session on exacerbations, patients are randomized to either 1) exacerbation self-management support through the use of a paper exacerbation action plan (con
or 2) exacerbation self-management support through the use of the ACCESS system (intervention group). Participants in the intervention group receive the instruction to use ACCESS when they notice a

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age >= 40 years; - confirmed diagnosis of COPD by spirometry (post-bronchodilator FEV1/FVC = 2 consecutive days in either >= 2 major symptoms (dyspnea, sputum purulence, sputum amount) or any 1 major symptom plus any >= 1 minor symptoms (colds, wheeze, sore throat, cough)

Exclusion criteria

Exclusion criteria: - self-reported co-morbid conditions that prohibit participation; - unable to communicate in the Dutch language; - severe difficulties using a smartphone

Design outcomes

Primary

MeasureTime frame
Primary aim: to improve the number of exacerbation-free weeks.

Secondary

MeasureTime frame
Secondary aims: to improve exacerbation self-management, exacerbation-management related self-efficacy, and quality of life. To decrease ER visits, hospital admissions and COPD related costs.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)